Updates from the CAPTIVATE Study Evaluating Ibrutinib + Venetoclax in TN CLL/SLL

Opinion
Video

An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.

Video content above is prompted by the following questions:

  • Please briefly discuss the ongoing CAPITIVATE trial, evaluating ibrutinib plus venetoclax for the treatment of treatment naïve CLL/SLL.
    • Please discuss the latest data from the CAPTIVATE trial.
      • What are the key takeaways from the results of this study?
      • How do the outcomes impact patients with high-risk genomic features?
Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
FDA Updates Fludarabine Labeling Under Project Renewal Initiative

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

Jordyn Sava
November 20th 2024
Article

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine

Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine

Jordyn Sava
November 13th 2024
Article

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Breakthroughs and Challenges in BCL-2 Inhibitor Therapy for CLL Treatment

Breakthroughs and Challenges in BCL-2 Inhibitor Therapy for CLL Treatment

Jordyn Sava
October 24th 2024
Article

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

Read More

Lipsky Discusses Second-Generation BTK Inhibitors in Relapsed/Refractory CLL

Lipsky Discusses Second-Generation BTK Inhibitors in Relapsed/Refractory CLL

Targeted Oncology Staff
October 12th 2024
Article

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with chronic lymphocytic leukemia.

Read More